Compare Gap Inc (GAP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Neurocrine Biosciences Inc — how do they compare? Gap Inc trades at $23.12 (market cap $8.21B), while Neurocrine Biosciences Inc trades at $141.37 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Gap Inc pays a 3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GAP | NBIX | |
|---|---|---|
Market Cap | $8.21B | $14.36B |
Volume | 5,192,917 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $185.50 |
52-Week Low | $18.35 | $123.10 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | $11.44B | $14.37B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The stock shows strong fundamentals with a low P/E of 7.04, robust ROE of 33.78%, and net income margin expansion to 8.14% in 2025. Recent earnings beats in Q1 and Q2 2026 and strategic moves into music partnerships signal brand revitalization efforts.
The outlook is positive given undervaluation, earnings momentum, and strategic initiatives, but risks include reliance on Old Navy's turnaround and competitive pressures. Upside to the price target offers potential, supported by institutional buying interest and solid cash flow generation.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
